8-K: Cullinan Therapeutics Presents Promising CLN-978 Data

Cullinan Therapeutics announced initial clinical data from its Phase 1 OUTRACE trials for CLN-978, showing clinical benefit and B cell depletion in patients with rheumatoid arthritis and systemic lupus erythematosus.

Summary

• Cullinan Therapeutics presented initial clinical data from its Phase 1 OUTRACE trials for CLN-978, a CD19xCD3 T cell engager, at the EULAR 2026 Congress.
• The data, based on 29 patients evaluated as of May 15, 2026, showed clinical benefit, including remissions, in patients with treatment-refractory rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) following a single target dose.
• CLN-978 demonstrated deep, dose-dependent B cell depletion in peripheral blood and tissue, with over 80% reduction from baseline in 82% of SLE patients and 67% of RA patients achieving depletion below the limit of quantification at target doses of 20g.
• The drug was generally well-tolerated across dose cohorts, with most cytokine release syndrome (CRS) events being Grade 1 and occurring after the first dose. A single Grade 3 CRS was observed at a 45g dose, leading to discontinuation of that cohort.
• Additional data for CLN-978 and initial data for velinotamig, a BCMAxCD3 T cell engager, will be presented at Cullinan's Immunology Day on June 10, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, with promising initial clinical data for CLN-978 demonstrating efficacy and a generally favorable safety profile, although a single Grade 3 CRS event warrants monitoring.

Positives

• Demonstrated clinical benefit, including remissions, in both SLE and RA patients after a single dose of CLN-978.
• Achieved deep and dose-dependent B cell depletion in peripheral blood and tissue, with 50% of SLE patients and 67% of RA patients treated at 20g doses achieving depletion below the limit of quantification.
• Showed improvement in all lab markers of disease activity (anti-dsDNA, UPCR, C3 and C4) in SLE patients with clinically significant abnormalities at baseline.
• Achieved a DAS28-ESR remission in one RA patient treated with a single 30g target dose.
• CLN-978 reduced RA autoantibody levels without impacting protective vaccine titers.
• The drug was well-tolerated across 10g, 20g, and 30g target dose cohorts.
• Subcutaneous administration supports potential for outpatient, community-based care.
• No immune effector cell-associated neurotoxicity syndrome (ICANS) was observed.

Negatives

• A single case of Grade 3 cytokine release syndrome (CRS) was observed following administration of the 45g target dose.
• Enrollment to the 45g cohort was discontinued due to the Grade 3 CRS event.

Risks

• The clinical trials are ongoing, and the presented data are interim and subject to change as more follow-up data is obtained.
• There is no assurance that the interim results will be predictive of final clinical trial results or that additional data will confirm these observations.
• Potential for material changes in the reported safety profile and clinical outcomes as patient enrollment continues.
• Risks related to regulatory submissions, INDs, NDAs, and clearance timelines.
• Uncertainty regarding the success of clinical trials and preclinical studies.
• Risks associated with protecting and maintaining intellectual property.
• Risks related to manufacturing, supply, and distribution of product candidates.
• Risk that product candidates will not be successfully developed and commercialized.

Future Outlook

The company is focused on advancing CLN-978 rapidly through global clinical development. Additional data for CLN-978 and initial data for velinotamig will be presented at the company's Immunology Day on June 10, 2026. Future data presentations are planned.

Management Comments

• "These initial Phase 1 data demonstrate the deep and dose-dependent B cell depletion achievable with CLN-978 and reinforce our belief that it has strong potential as a disease-modifying treatment in multiple challenging-to-treat autoimmune conditions."
• "But just as important, the emerging safety profile and subcutaneous administration support the potential to deliver substantial clinical benefit to patients in the outpatient, community-based care setting."
• "With study of multidose regimens underway, we are focused on advancing CLN978 rapidly through global clinical development to accelerate bringing this new therapeutic option to patients."
• "The data emerging from this program represent one of the most comprehensive and rigorous datasets generated to date across multiple indications and biomarkers, and help to inform further clinical development of this program as well as how these therapies may be ultimately used in clinical practice."
• "In many patients, a single target dose of CLN978 demonstrated rapid depletion of B cells not just in in peripheral blood, but notably also clearance of CD19+ B cells in lymph node and synovial tissue."
• "The encouraging safety profile and clear dose-dependent effects provide strong evidence of the underlying mechanism of action."

Industry Context

StockSavvy.ai notes that the presentation of initial clinical data for CLN-978 at EULAR 2026 positions Cullinan Therapeutics within the competitive landscape of autoimmune disease therapeutics, particularly those targeting B cells. The focus on T cell engagers for autoimmune conditions aligns with emerging trends in the field, aiming to offer more targeted and potentially disease-modifying treatments beyond traditional immunosuppressants.

Stakeholder Impact

• Shareholders: Positive impact due to promising clinical data that could lead to future product development and commercialization.
• Patients with RA and SLE: Potential for a new, disease-modifying treatment option for those with refractory disease.
• Healthcare Providers: Data provides insights into the potential use and management of CLN-978 in clinical practice.

Next Steps

• Continue global clinical development of CLN-978.
• Present new data from the first RA multi-dose regimen cohort for CLN-978 at Immunology Day on June 10, 2026.
• Present initial clinical data for velinotamig at Immunology Day on June 10, 2026.
• Implement additional step-up dosing in multi-dose regimens for CLN-978, if deemed appropriate.

Key Dates

Recommendation

The initial Phase 1 data for CLN-978 are encouraging, demonstrating clinical benefit and B cell depletion in RA and SLE patients. However, these are early-stage results, and further clinical development, including larger trials and long-term safety data, is required. The single Grade 3 CRS event also warrants careful monitoring. Therefore, a 'hold' recommendation is appropriate pending more comprehensive data.

Keywords

Cullinan Therapeutics, CLN-978, Rheumatoid Arthritis, Systemic Lupus Erythematosus, T cell engager, Phase 1 trial, EULAR, B cell depletion